WaveSpan-010NCT07917754
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Participants will receive escalating doses (2 to 120mg) of MK-1045 (or in Part 2, a dose of MK-1045 determined by Part 1) via intravenous infusion (IV) once weekly (q1w) for 48 weeks plus 1.5 or 1.75 mg/kg ZV via IV infusion once every 3 weeks (q3w) for 18 weeks. Participants may continue to receive MK-1045 once every 2 weeks (q2w) after 3 months if a Complete Response (CR) is achieved.
Participants will receive physician's choice of: 12 mg/kg tafasitamab per labeling instructions plus 25mg lenalidomide once daily (qd) from Days 1-21 of each cycle (each cycle is 28 days) for up to 12 cycles followed by 12 mg/kg tafasitamab monotherapy q2w if stable OR 1.8 mg/kg polatuzumab vedotin plus 90 mg/m\^2 bendamustine and 375 mg/m\^2 rituximab (or biosimilar) q3w for 6 cycles (each cycle is 21 days).
Biologicals: MK-1045, Zilovertamab vedotin, Rituximab, Rituximab biosimilar, Polatuzumab vedotin, Lenalidomide, Tafasitamab, Rescue Medication - Biological
Drugs: Bendamustine, Rescue Medications - Drug
Other: Granulocyte-colony stimulating factor (G-CSF)